echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Stanford University $12 million for stem cell trials

    Stanford University $12 million for stem cell trials

    • Last Update: 2021-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    The California Institute for Regenerative Medicine (California Institute for Regenerative Medicine) allocated nearly $12 million to support a new clinical trial of cell-based therapies to improve the efficacy and survival of children and young blood cancer patients receiving stem cell transplants


    This treatment, named T-allo10, aims to improve the immune response to pathogens and cancer without increasing the possibility of graft-versus-host disease in patients who must receive transplants from an incompletely matched donor


    The trial will be led by Maria Grazia Roncarolo, MD, professor of pediatrics and medicine


    "In California, approximately 500 children receive stem cell transplants each year.


    At present, the treatment standard for many blood cancers is divided into two parts: chemotherapy is used to destroy the patient's cancer cells, and then blood and immune stem cells are transplanted from an immune-matched donor


    Roncarolo and her team will test T-allo10, which means that mature immune cells are used simultaneously with type 1 regulatory T cells or Tr1 cells from donors after stem cell transplantation


    T-allo10 aims to improve transplant outcomes by reducing cancer recurrence and infection rates and the possibility of graft-versus-host disease


    Roncarolo said: "My team and I are very pleased to receive CIRM's support for our immunotherapy clinical trials, which may help leukemia patients receive hematopoietic stem and progenitor cell transplants from non-exactly matched donors-this group continues to suffer Terrible results and high unmet needs



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.